Patents for A61P 35 - Antineoplastic agents (221,099)
07/2008
07/31/2008WO2008091781A1 Reducing tumor growth
07/31/2008WO2008091643A2 Evaluating synergy of combinations comprising an antibody in immune suppressive pathways concurrent to immunotherapy
07/31/2008WO2008091620A2 Combination therapy comprising romidepsin and i.a. bortezomib
07/31/2008WO2008091530A2 Diagnostic and therapeutic cyclooxygenase-2 binding ligands
07/31/2008WO2008091222A1 Dll4 signaling inhibitors and uses thereof
07/31/2008WO2008090960A1 Genetically recombinant antibody composition capable of binding specifically to ganglioside gm2
07/31/2008WO2008090944A1 Spiro-ring compound
07/31/2008WO2008090884A1 Novel trifluoromethylphenyltetrahydrocinnoline derivative and pharmaceutical use thereof
07/31/2008WO2008090850A1 Agent for enhancing the effect of anticancer agent
07/31/2008WO2008090732A1 Pharmaceutical composition
07/31/2008WO2008090717A1 Adam inhibitor
07/31/2008WO2008090565A1 Novel thermodynamically stable polymorphic form-l of letrozole
07/31/2008WO2008090356A1 Thiazolidinone derivatives useful in the treatment of cancer and disorders caused by excess adiposity
07/31/2008WO2008090355A2 Inhibitors of stem cells markers
07/31/2008WO2008090353A1 3 - cinnolinecarboxamide derivatives and their use for treating cancer
07/31/2008WO2008090327A1 New combination for use in the treatment of cancer
07/31/2008WO2008090177A2 Diagnosis of prostate cancer
07/31/2008WO2008090081A1 Metal salophen complexes for prevention and treatment of cancer
07/31/2008WO2008089674A1 Cyclohexenone extractant of antrodia camphorata
07/31/2008WO2008089645A1 Fusion polypeptide inhibiting cell growth and use thereof
07/31/2008WO2008089628A1 A nanoparticle of glucidamin for treating tumor and preparation method thereof
07/31/2008WO2008089602A1 The tetracyclic anthraquinones possessing anti-cancer effect
07/31/2008WO2008089594A1 Use of phthalide dipolymers for antitumor
07/31/2008WO2008089581A1 Fused aromatic ptp-1b inhibitors
07/31/2008WO2008089567A1 Cancerous disease modifying antibodies
07/31/2008WO2008089566A1 Cancerous disease modifying antibodies
07/31/2008WO2008089565A1 Cancerous disease modifying antibodies
07/31/2008WO2008068507A3 2 -phenylamino, 6- (pyrid-3-yl) quinazoline derivatives as raf-protein kinase inhibitors in cancer treatment
07/31/2008WO2008068429A3 Composition for the prevention and/or treatment of diseases associated with tnf and/or il-12 overexpression
07/31/2008WO2008065428A3 Steroid sulphatase inhibitors for treating hormone dependent cancer
07/31/2008WO2008065409A3 Combination for use in the treatment of cancer, comprising tamoxifen or an aromatase inhibitor
07/31/2008WO2008065282A3 Substituted pyrazoles, compositions containing these, method of production and use
07/31/2008WO2008065282A2 Substituted pyrazoles, compositions containing these, method of production and use
07/31/2008WO2008061236A3 Sulfoximines as kinase inhibitors
07/31/2008WO2008059068A3 Carbonyl-substituted titanocenes
07/31/2008WO2008056188A3 Novel compounds and methods for their production
07/31/2008WO2008051797A3 Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
07/31/2008WO2008051795A3 Preventing or reducing oxidative stress or oxidative cell injury by the administration of a water-insoluble cellulose derivative
07/31/2008WO2008045267A3 Pyrazolopyrimidines as cyclin dependent kinase inhibitors
07/31/2008WO2008036653A3 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
07/31/2008WO2008035365A3 Rna interference mediated inhibition of aurorakinase b and its combinations as anticancer therapy
07/31/2008WO2008031061A3 Anti-activin a antibodies and uses thereof
07/31/2008WO2008023283A3 Stabilized esters of lutein
07/31/2008WO2008019366A3 Methods and compositions for increased priming of t-cells through cross-presentation of exogenous antigens
07/31/2008WO2008016793A3 Methods, compositions and articles of manufacture for contributing to the treatment of cancers
07/31/2008WO2008008493A8 Alkyne-substituted pyridone compounds and methods of use
07/31/2008WO2007141533A3 Fkbp-l and uses thereof
07/31/2008WO2007134298A3 Therapeutic compounds and their use in cancer
07/31/2008WO2007127010A3 Diarylthiohydantoin compounds
07/31/2008WO2003064596A8 Desaturase genes, enzymes encoded thereby, and uses thereof
07/31/2008US20080182981 Method and medicament for inhibiting the expression of a given gene
07/31/2008US20080182977 Molecules associated with cell proliferation
07/31/2008US20080182975 Framework-Patched Immunoglobulins
07/31/2008US20080182900 Method of treatment of virus infections using shikonin compounds
07/31/2008US20080182883 e.g. 1-Benzyl-3-pentyl-2-[6-(1H-tetraazol-5-ylmethoxy)-2-naphthyl]-1H-indole; stroke associated with or resulting from atrial fibrillation; thrombolytic agents for prohylaxis of cardiovascular disorders
07/31/2008US20080182879 e.g. 6-hydroxy-2-[3-(4-tert-butylphenyl)-1,2,4-oxadiazol-5-yl]chromone; tyrosine kinase inhibitors, anticarcinogenic and antiinflammatory agent; cerebral, genito-urinary tract, lymphatic system, stomach, laryngeal, pancreatic, breast or lung tumor; rheumatoid arthritis, psoriasis, contact dermatitis
07/31/2008US20080182871 e.g. 3-(3-methoxyphenyl)isoquinolin-1-amine; antiproliferative and antigrowth agent; breast tumors, prostate tumors, colon tumors, ovary tumors, kidney tumors, pancreas tumors, glioblastoma and melanoma.
07/31/2008US20080182867 Administering one or more rapamycin derivatives (including rapamycin and 40-O-(2-hydroxy)ethyl-rapamycin); lymphocytic leukemia, lymphoma, Epstein-Barr virus, inhibiting graft rejection and metastasis; drug screening
07/31/2008US20080182857 Heat Shock Protein 90 inhibitors; 5-(2,4-dihydroxyphenyl)-4-(naphth-1-yl)-4H-1,2,4-triazole-3-thiol; incorrect protein folding or aggregation; hydrazonederivatives react with dimiadazole cabonyl/thiocarbonyl derivatives; hydrazines derivatives react with isocyanate or isothiocyanates; tumors, cancer
07/31/2008US20080182852 Anthranilamide inhibitors of aurora kinase
07/31/2008US20080182844 7-Substituted Aza-Indazoles, Compositions Containing Same, Production Method and Use Thereof
07/31/2008US20080182843 Mitotic Kinesin Inhibitors
07/31/2008US20080182842 L-alanine derivatives as a5beta1 antagonists
07/31/2008US20080182840 Inhibitors of the FAK (focal adhesion kinase) protein tyrosine kinases, antiproliferative, antitumor; for example 5-{4-[(1-Hydroxy-cyclopentylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one
07/31/2008US20080182837 New chemical compounds
07/31/2008US20080182834 less toxic than the unassociated metal complex by hindering reactions in the blood stream; antitumor agents; platinum, palladium, gold amine inclusion compounds
07/31/2008US20080182829 8Beta-Hydrocarbyl-Substituted Estratrienes As Selectively Active Estrogens
07/31/2008US20080182816 Utilizing prodrug technique to couple polysaccharides containing galactose with a parent compound through different bridge linkage to derive conjugates; polysaccharide component protects 5-fluorouracil(5-FU) from absorption in the upper gastrointestinal tract, delivers the 5-FU to colorectal area
07/31/2008US20080182807 gene therapy against tumors and cancer; expression vector includes insert into tumor an effective amount of polynucleotides encoding a functionally active p53, express p53 to first DNA damaging agent, contact tumor cell with first DNA damaging agent, and kill tumor cell
07/31/2008US20080182803 extract from Cassia or Senna plants comprises rubrofusarin gentiobioside with egg white, egg membrane, milk whey, yeast/vegetable proteins, soy bean, L-cysteine, L-methionine, and vitamin C; synergistic; intracellular biosynthesis of glutathione stimulator; liver, brain, vision, or immune disorders
07/31/2008US20080182797 Short peptides comprising the amino acid sequence Cys-Glu-Phe-His as well as analogs and derivatives thereof, which peptides efficiently denitrate cellular proteins and thus prevent tissue damage associated with excess nitric oxide and its reactive species; protection against ischemia/reperfusion injury
07/31/2008US20080182794 Methods for treating breast cancer using nrif3 related molecules
07/31/2008US20080182791 Medicament for Improving Prognostic Survival in Therapy of Malignant Tumor
07/31/2008US20080182782 Truncated cytochrome c551 for use as therapeutic agents in prevention and treatment of viral infection and cell proliferative dsorders
07/31/2008US20080182777 Regulation of cell migration and adhesion
07/31/2008US20080182314 Neuronal serine threonine protein kinase
07/31/2008US20080182302 Open reading frames which encode polypeptides sufficient to direct the biosynthesis synthesis of a safracin molecule having improved properties and that could be used in the hemi-synthesis of new ecteinascidins compounds; combinatorial chemistry; antitumor agents; broad-spectrum antibiotics; bactericides
07/31/2008US20080182292 Investigation of new membrane tubes containing F-actin and myosin of a diameter of 50-400 nm and <50+ micrometers length which span the cells; spreading, incubating and staining with a detectable microscopic stain, fluorescent dye, to obtain stained plasma membranes for 3-D cell microscopy
07/31/2008US20080181971 antibiotic; synergistic with one or more of 5-fluorouracil, bortezomib, camptothecin, carmustine, cisplatin, doxorubicin, etoposide, gemcitabine, methotrexate, and paclitaxel;anticarcinogenic ; human and veterinary medicine
07/31/2008US20080181963 Dermatological/cosmetic gels comprising at least one retinoid and benzoyl peroxide
07/31/2008US20080181954 Genetically altered chondrocyte expresses a therapeutic agent; implanting a biocompatible substrate into a target region; brain, heart, liver, kidney, intestinal tract, spleen, smooth and skeletal muscles, eye, ganglions, lungs, gonads, pancreas
07/31/2008US20080181939 hydrolysis triggered, controlled release polymersome nano-system for delivering a cytotoxic, anticancer therapeutic active agent to cell; stable, synthetic, self-assembling, controlled release, polyethylene oxide-based vesicles; semi-permeable, thin-walled, amphiphilic, high molecular weight
07/31/2008US20080181928 stent; coating comprising a dry film comprising at least one lipid bilayer and at least one pharmaceutically effective agent; Upon exposure to an aqueous fluid, liposomes are released
07/31/2008US20080181891 Modified human igf-ir antibodies
07/31/2008US20080181877 bioassay of forskolin or phorbol 12-myristate 13-acetate; increase sensitivity of the protein kinase A signalling pathway, increase insulin sensitivity, thermogenesis; obesity, type 2 diabetes, insulin resistance, hypertriglyceridemia, cancer, increase plasma levels of free fatty acids
07/31/2008US20080181870 brain cancer treatment with a mixture of a viral vector and ganciclovir; delivered to target cells; provide prolong survival
07/31/2008US20080181864 Reducing mitochondrial membrane potential in mammalian cell by administering an major histocompatibility complex (MHC) class II HLA-DR (human leukocyte antigen) ligand; control disease by manipulating mitochondrial metabolism; drug screening antitumor drug; treating human breast cancer
07/31/2008US20080181852 water soluble polyglutamnylglutamine conjugated to drugs, polydentate ligands, targeting, optical imaging, magnetic resonance imaging or stabilizing agents, having improved bioavailability
07/31/2008US20080181849 Methods, kits and compositions comprising crotamine
07/31/2008US20080179246 Method of obtaining a natural hydroxytyrosol-rich concentrate from olive tree residues and subproducts using clean technologies
07/31/2008DE102007010815B3 New N-phenylsulfonyl-3-amidino-phenylalanine piperidide derivatives useful as antitumor agents
07/31/2008CA2676436A1 Diagnosis of prostate cancer
07/31/2008CA2676413A1 Diagnostic and therapeutic cyclooxygenase-2 binding ligands
07/31/2008CA2676387A1 Combination therapy
07/31/2008CA2676257A1 Anthranilamide inhibitors of aurora kinase
07/31/2008CA2676105A1 The tetracyclic anthraquinones possessing anti-cancer effect
07/31/2008CA2676008A1 Compositions and methods for diagnosing and treating cancer
07/31/2008CA2675621A1 3 - cinnolinecarboxamide derivatives and their use for treating cancer
07/31/2008CA2675293A1 Cancerous disease modifying antibodies
07/31/2008CA2675292A1 Cancerous disease modifying antibodies